Web18 gen 2024 · HIMALAYA was a randomised, open-label, multicentre, global Phase III trial of Imfinzi monotherapy and the STRIDE regimen, comprising a single priming dose of … WebIntroduction: This integrated phase 3 analysis examined efficacy and cardiovascular safety for roxadustat vs erythropoiesis-stimulating agents (ESAs) in dialysis-dependent patients. Methods: Efficacy and safety results from four phase 3, randomized, open-label studies comparing roxadustat to ESAs (PYRENEES, SIERRAS, HIMALAYAS, ROCKIES) in …
Tremelimumab plus Durvalumab in Unresectable ... - NEJM Evidence
Web25 set 2024 · In the phase 3 SQUIRE (Squamous NSCLC treatment with the Inhibitor of EGF Receptor) trial involving patients with untreated metastatic, squamous NSCLC, the median overall survival was 1.6 months ... Web20 set 2024 · Purpose: This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring a … knmi archief
Himalaya Early Access Program - Full Text View - ClinicalTrials.gov
Web1 apr 2024 · Abstract. In the phase III HIMALAYA trial, a single priming dose of tremelimumab plus once-monthly durvalumab was associated with better overall survival … WebNational Center for Biotechnology Information Web24 ott 2024 · Approval is based on positive results from the phase 3 HIMALAYA trial, presented in June 2024 at the American Society of Clinical Oncology annual meeting. ... knmi ballon verwachting